Carter's Reports Strong Q1 Sales Growth, Beats EPS Estimates Amid Profitability Pressures
summarizeSummary
Carter's reported strong Q1 sales growth and improved cash flow, significantly beating recent analyst EPS expectations, but profitability declined due to cost pressures, and the company reiterated a negative full-year EPS outlook.
check_boxKey Events
-
Strong Q1 Sales Growth
Net sales increased 8.1% to $681.1 million, with U.S. Retail comparable sales up 10.5%, marking the fourth consecutive quarter of growth.
-
Significant EPS Decline
Diluted EPS decreased to $0.39 from $0.43 (GAAP) and adjusted diluted EPS fell to $0.39 from $0.66 in Q1 2025, primarily due to higher tariffs, investment spending, and inflationary costs.
-
Improved Operating Cash Flow
Net cash provided by operations was $6.4 million, a significant improvement compared to net cash used of $48.6 million in the prior year period.
-
Reiterated Full-Year Outlook with EPS Decline
The company reaffirmed its full-year fiscal 2026 outlook for low single-digit to mid-single-digit percentage growth in net sales and adjusted operating income, but projects a low double-digit to mid-teens percentage decline in adjusted diluted EPS.
auto_awesomeAnalysis
This 8-K reports Carter's Q1 fiscal 2026 results, presenting a mixed financial picture. While the company achieved strong top-line growth, particularly with an 8.1% increase in net sales and a robust 10.5% rise in U.S. Retail comparable sales, profitability was significantly impacted. Adjusted diluted EPS declined by 41% year-over-year, primarily due to higher tariffs, increased investment spending, and inflationary pressures. However, the reported EPS of $0.39 significantly exceeded recent analyst projections of $0.13, which could be viewed positively by the market as a beat against lowered expectations. The company also demonstrated improved operating cash flow. Management reiterated its full-year sales and operating income growth outlook, but maintained a forecast for a low double-digit to mid-teens percentage decline in full-year adjusted EPS, and provided weak guidance for Q2 EPS. Investors will likely focus on the continued sales momentum and cash flow improvement, while monitoring the company's ability to mitigate cost pressures and improve bottom-line performance in the coming quarters, especially under the new CEO.
At the time of this filing, CRI was trading at $33.34 on NYSE in the Manufacturing sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $23.38 to $44.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.